Novo Nordisk: Pills instead of Injections - Obesity Therapies Offer Long-Term Potential!

For investors currently seeking diversification in the healthcare sector, I find Novo Nordisk (i.) interesting. After the focus has been on obesity therapies via weight loss injections, oral tablets are now becoming a viable alternative. A daily pill can be prescribed much more smoothly in primary care and can be integrated into daily life significantly easier. The proven average weight loss of 13.6% with the oral Wegovy variant also impressively demonstrates that this convenience does not come at the expense of clinical efficacy. Critics often...